Curated News
By: NewsRamp Editorial Staff
October 27, 2025
NanoViricides to Present Antiviral Pipeline at PODD 2025 Conference
TLDR
- NanoViricides' broad-spectrum antiviral platform offers investors first-mover advantage in treating multiple viruses with NV-387 advancing toward Phase II trials.
- NanoViricides develops antiviral drugs using nanoviricide technology licensed from TheraCour, with NV-387 showing preclinical efficacy against RSV, Influenza, and Coronaviruses.
- NanoViricides' antiviral pipeline could significantly reduce global suffering from respiratory viruses, MPox, and other infectious diseases through broad-spectrum treatments.
- NanoViricides is developing a single drug platform that fights multiple viruses including RSV, Influenza, Coronaviruses, and MPox using innovative nanomedicine technology.
Impact - Why it Matters
The development of broad-spectrum antiviral drugs like NanoViricides' NV-387 represents a crucial advancement in global healthcare preparedness. With respiratory viruses causing significant morbidity and mortality worldwide, and the recent COVID-19 pandemic highlighting vulnerabilities in our antiviral arsenal, effective treatments that can target multiple viruses simultaneously could revolutionize how we respond to viral outbreaks. Success in this area would provide healthcare providers with powerful tools to combat seasonal influenza, RSV outbreaks, and potential future pandemics, reducing hospitalizations and saving lives. For investors, this represents an opportunity in the growing antiviral therapeutics market, while for the general public, it offers hope for more effective treatments against common and emerging viral threats that impact millions annually.
Summary
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing broad-spectrum antiviral drugs, will present at the PODD 2025 Conference on October 27th, where President and Executive Chairman Anil R. Diwan, PhD, will provide updates on the company's antiviral drug pipeline and platform technologies available for licensing. The company's lead candidate, NV-387, is advancing toward Phase II trials for MPox and respiratory viral infections, with preclinical studies demonstrating strong efficacy against RSV, Influenza A, and Coronaviruses. This presentation represents a significant opportunity for the company to showcase its innovative nanoviricide technology platform to potential partners and investors in the pharmaceutical industry.
The company's business model is built on licensing technology from TheraCour Pharma Inc. for specific antiviral applications, with NanoViricides holding exclusive, sub-licensable field licenses for numerous viral diseases including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex, Influenza, Dengue, Ebola/Marburg viruses, and certain Coronaviruses. Beyond NV-387, the company is developing NV-HHV-1 for shingles treatment and has research programs targeting oral and genital Herpes, viral eye diseases, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus. The company's platform technology is based on the TheraCour nanomedicine technology licensed from AllExcel, creating special purpose nanomaterials specifically designed for antiviral therapy with the goal of preventing viral escape mechanisms.
Investors can access the latest news and updates relating to NNVC through the company's newsroom at the InvestorBrandNetwork, which provides comprehensive corporate communications solutions including wire-grade press release syndication, article and editorial syndication to over 5,000 outlets, enhanced press release services, and social media distribution to millions of followers. The InvestorWire platform, powered by IBN's Dynamic Brand Portfolio, serves as a specialized communications channel for companies seeking to reach wide audiences of investors, consumers, and journalists while cutting through today's information overload to achieve unparalleled recognition and brand awareness in the competitive pharmaceutical development space.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides to Present Antiviral Pipeline at PODD 2025 Conference
